Pulse Biosciences (NASDAQ:PLSE) Rating Increased to Sell at StockNews.com

Pulse Biosciences (NASDAQ:PLSE) was upgraded by investment analysts at StockNews.com to a “sell” rating in a note issued to investors on Friday.

Pulse Biosciences Stock Down 4.6 %

Shares of Pulse Biosciences stock opened at $17.87 on Friday. Pulse Biosciences has a 12-month low of $3.78 and a 12-month high of $22.69. The business’s 50 day moving average is $17.63 and its 200-day moving average is $12.63. The stock has a market cap of $986.87 million, a P/E ratio of -22.06 and a beta of 1.75.

Institutional Investors Weigh In On Pulse Biosciences

Institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets increased its position in Pulse Biosciences by 63.6% during the first quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock worth $66,000 after buying an additional 2,952 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new position in shares of Pulse Biosciences during the 1st quarter worth approximately $88,000. Quest Partners LLC acquired a new position in shares of Pulse Biosciences during the 2nd quarter worth approximately $91,000. Cetera Advisors LLC bought a new stake in Pulse Biosciences in the 1st quarter valued at $109,000. Finally, PNC Financial Services Group Inc. bought a new stake in Pulse Biosciences in the 4th quarter valued at $242,000. 76.95% of the stock is owned by institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.